

# AVACEN Medical Begins Crowdfunding Round on StartEngine.com

*Offers Ownership Participation for Only \$500!*

CARLSBAD, CALIFORNIA, UNITED STATES, July 5, 2023 /

EINPresswire.com/ -- [AVACEN Medical](#), a leading developer and manufacturer of noninvasive, drug-free, FDA-Cleared Class II thermotherapy devices, announced today its launch of a \$5 million raise on [StartEngine.com](#).

The capital raised will be used to complete the development of 3 new medical devices aimed at the perioperative market and follow-on clinical studies in the areas of type 2 diabetes and fibromyalgia, as well as a wound healing study. The results from the studies will be used to support FDA applications for marketing clearance.



“

"According to StartEngine: 'Of close to 3,000 applications to raise capital on our platform this year, we've greenlit less than 50. That makes [StartEngine] more exclusive than Harvard.'"

*Thomas Muehlbauer*

The AVACEN team is backed by successful leaders who have helped the company secure 17 patents and complete 10 pilot studies all supporting billion-dollar market opportunities such as chronic pain, type 2 diabetes, wound healing, fibromyalgia, and opioid addiction.

Thomas Muehlbauer, Chairman of AVACEN Medical stated, "According to StartEngine: 'Of close to 3,000 applications to raise capital on our platform this year, we've greenlit less than 50. That makes [StartEngine] more exclusive than Harvard.' AVACEN is honored to be one of those rare companies to be selected."

AVACEN's newest third generation thermotherapy devices include the HOME XL™ for home-based users, as well as the PRO+™ for professional users, which includes a commercial license to

charge for treatments. The Company also recently launched its first cardiac diagnostic device, also FDA-Cleared Class II, called the CSS™ (Cardiac Stress & Screening). The reimbursable device provides a 1, 3, and 5-minute test to examine arterial health, heart rate variability, autonomic nervous system balance and stress resiliency.

About AVACEN Medical: AVACEN Medical, a rapidly rising INC. 5000 company for the last four years, holds 17 worldwide medical device patents. The Company is dedicated to the innovation, design, and manufacture of safe, easy-to-use, drug-free alternatives for the noninvasive management of pain and wellness associated with numerous chronic and acute conditions including the temporary relief of minor muscle and joint pain and stiffness associated with arthritis and potentially other conditions that can cause joint pain, such as CRPS, Raynaud's, and Lyme disease. Founded in 2009, AVACEN Medical is headquartered in Carlsbad, CA. Contact: Anthony Shimkin, CEO at (888) 428-2236 x715 or [ashimkin@avacen.com](mailto:ashimkin@avacen.com).

Thomas G Muehlbauer  
AVACEN, INC.

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[Instagram](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/643184924>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.